Augmentation in Restless Legs Syndrome: When Dopamine Medicines Make Symptoms Worse

Table of Contents

1. What Augmentation Is
2. The Max Planck Institute Criteria
3. How Often It Happens With Each Medicine
4. How the Risk Builds Over the Years
5. Risk Factors the Studies Report
6. Why the 2025 Guideline Changed
7. How Consensus Statements Describe Management
8. Impulse Control, Sleep Attacks and Other Side Effects
9. Coming Off a Dopamine Agonist
10. What Is Not Known
11. Key Research Papers
12. Connections
13. Featured Videos

What Augmentation Is

Augmentation is a worsening of restless legs symptoms caused by the treatment itself. The authors of a 52-week trial in the New England Journal of Medicine describe it as the “iatrogenic worsening” of the condition with long-term dopamine treatment — iatrogenic meaning brought on by medical care. A 2007 international consensus conference called it “the main complication of dopaminergic treatment” of restless legs syndrome.

The changes people notice fall into a few groups:

• Earlier onset: symptoms that used to begin late in the evening now begin in the afternoon, or even the morning.
• Spread: the urge to move reaches the arms or other parts of the body, not only the legs.
• Shorter latency: symptoms appear sooner after sitting or lying down.
• Greater intensity: symptoms are stronger when they do come.
• A paradoxical response to dose changes: the consensus conference described this as another sign of augmentation.

The pramipexole prescribing label describes augmentation in the same terms: “the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities.” The label separates it from rebound, which it defines as “a worsening of symptoms following treatment cessation with greater intensity than described before starting treatment.” Rebound happens when a dose wears off or the medicine is stopped; augmentation happens while the medicine is still being taken.

Telling early augmentation apart from the ordinary ups and downs of the condition is hard: the authors of a 6-month pramipexole trial wrote that “beginning or mild augmentation is difficult to distinguish from natural RLS fluctuation.”

Back to Table of Contents

The Max Planck Institute Criteria

In April 2006 the European Restless Legs Syndrome Study Group held a consensus conference at the Max Planck Institute in Munich. Its conclusions were endorsed by the International Restless Legs Syndrome Study Group (IRLSSG) and the World Association of Sleep Medicine, and published in 2007 as the Max Planck Institute (MPI) diagnostic criteria for augmentation. They replaced an earlier definition drawn up at a 2002 National Institutes of Health conference.

The conference identified five major diagnostic features:

1. the usual time of day the symptoms begin;
2. the number of body parts with symptoms;
3. how quickly symptoms appear at rest;
4. how severe the symptoms are when they occur;
5. how the dopamine medicine affects the symptoms.

From the data it reviewed, the conference concluded that the best working definition was either a 4-hour advance in the usual starting time of symptoms, or a combination of the other features. It added that a paradoxical response to changes in dose also points to augmentation, and it set out a separate definition of clinically significant augmentation. Later studies used these criteria or the earlier ones: the rotigotine analyses below applied the Max Planck Institute criteria, the ropinirole study the National Institutes of Health criteria, and in both, expert panels reviewed the cases.

All five features are judged from the person's account of how the symptoms have changed. The International Restless Legs Syndrome Study Group's general diagnostic criteria for restless legs syndrome itself are set out on the main page.

Back to Table of Contents

How Often It Happens With Each Medicine

Reported rates range from a few percent to more than half of patients. The spread depends mostly on how long people were followed, which medicine and dose they took, and whether the study was a short controlled trial or years of real-world care.

Levodopa

Levodopa has the highest reported rates. In a European prospective study of 65 patients, most of them never treated before, levodopa was raised as needed up to 600 mg a day. Of the 60 people with usable data, augmentation occurred in 60% (36 of 60) within six months, and the median time to its appearance was 71 days. Seven of the 60 (11.7%) dropped out because of it; the authors noted that most people tolerated it over those six months. A 2016 meta-analysis put the pooled augmentation rate for levodopa at 27.1%.

Pramipexole

• In a 26-week placebo-controlled trial of 331 patients (doses 0.125–0.75 mg a day), the 6-month incidence of confirmed augmentation was 9.2% on pramipexole and 6.0% on placebo. The rate rose with treatment duration on pramipexole but not on placebo. Only people with ferritin above 30 ng/mL were enrolled. The pramipexole label reports augmentation in a 26-week trial at 12% on pramipexole and 9% on placebo.
• In the 52-week trial of 719 participants, augmentation over 40 or 52 weeks occurred in 7.7% of people on pramipexole 0.5 mg and 5.3% on 0.25 mg, against 2.1% on pregabalin. The difference was statistically significant for the 0.5 mg dose but not for 0.25 mg. Put the other way, about 92% of people on the higher pramipexole dose did not develop augmentation within that year.
• In a long-term clinic cohort of 50 people first given pramipexole between 1998 and 2002 and followed for a mean of 8 years, augmentation developed in 42%, after a mean of 16.5 months and no later than 4.1 years after starting. The median daily dose rose from 0.38 mg to 1.0 mg over the study.
• In a Japanese clinic study of 42 people followed for more than 18 months, augmentation developed in only 2 (4.8%). The authors suggested lower doses, iron levels and ethnic differences as possible reasons for the low rate.

Ropinirole

A prospective multicenter study gave ropinirole or placebo for 26 weeks, then open-label ropinirole for 40 more weeks (66 weeks in all). It enrolled 404 people with no previous augmentation. Augmentation occurred in 3.5% on ropinirole and under 1% on placebo during the double-blind phase, and in 3% during the open-label phase; clinically significant augmentation occurred in 3%, under 1% and 2%. Half of those with augmentation (7 of 14) stopped treatment. The authors reported that new first cases kept accumulating at a stable rate for the whole study.

Rotigotine (skin patch)

• Experts re-examined two 6-month placebo-controlled trials (745 people on rotigotine, 214 on placebo) and two 1-year open-label trials (620 people) using the Max Planck Institute criteria. In the double-blind trials, 8.2% of all participants met the criteria for augmentation at least once, but clinically relevant augmentation was found in 1.5% on rotigotine (11 people) and in 1 person on placebo. In the open-label trials, 9.7% met the criteria and 2.9% had clinically relevant augmentation. No one stopped because of augmentation within 1.5 years.
• In the 5-year open-label extension of 295 patients, clinically significant augmentation was recorded in 39 (13%): 15 of them (5% of the whole group) on 1–3 mg a day, the dose range approved in Europe, and 24 (8%) on 4 mg a day. Over the five years 57% stopped the patch, 30% because of side effects, and 19% because of skin reactions at the patch site.

The pooled picture

A 2016 meta-analysis of 60 studies and 11,543 people with primary restless legs syndrome put the overall augmentation rate at 5.6% (6.1% for long-term and 3.3% for short-term treatment). By drug group it found 27.1% for levodopa, 6.0% for dopamine agonists and 0.9% for pregabalin or gabapentin. Immediate-release medicines carried a 7.2% rate and the skin patch 1.7%. The authors titled their paper “Incidence of augmentation … may not be that high”; they also noted that the rates could not be analysed by dose, sex, age or symptom severity.

Studies of people in everyday care find higher figures than the trials. An online survey of 266 people taking dopamine medicines for restless legs syndrome, recruited through their doctors, classified 20% as having definite or highly suggestive augmentation after an average of 2.7 years of treatment. Only 25% reported no sign of augmentation at all.

Back to Table of Contents

How the Risk Builds Over the Years

Short trials capture only the first months, while augmentation keeps appearing for years. Three long studies describe the pattern:

• The community survey estimated that augmentation occurred at about 8% a year for at least the first 8 years of dopamine treatment.
• A 10-year review of all patients treated at one tertiary center from 1997 to 2007 found annual augmentation rates that were fairly constant after the first year: 7% a year for pramipexole and 5% for pergolide (an older dopamine agonist), compared with 0% for methadone. Yearly discontinuation rates were 9% for pramipexole, 8% for pergolide and 0% for methadone. After 5 years, 58% were still taking pramipexole. The authors concluded that dopamine agonists “appear to have a limited period of clinical utility for many patients,” and that severe augmentation “can develop even after years on the medication.”
• The 8-year pramipexole cohort found pramipexole “completely effective” in 40% at the end, compared with 67% at the end of the first study period; 58% called it partially effective. Even so, most of the group remained on the medicine.

A yearly rate of 5–8% looks small in any one year. Over a decade of treatment it adds up, which helps explain how trials reporting single-digit rates and clinics reporting rates near 40–60% can both be accurate.

Back to Table of Contents

Risk Factors the Studies Report

Higher dose

In the levodopa study, people who developed augmentation were more likely to be taking 300 mg a day or more (83% against 54%). In the 5-year rotigotine extension, 24 of the 39 clinically significant cases were on the highest 4 mg dose. The 2023 meta-analysis below found higher levodopa-equivalent doses in people with augmentation. The 2016 international task force noted, however, that “even low dose dopaminergics can cause augmentation.”

High doses are common in practice. An analysis of a United States prescription database covering 670,404 people with restless legs syndrome from 2017 to 2018 found that 58.8% were prescribed a dopamine agonist. Of all the patients in the database, 19.1% were prescribed doses above the maximum approved by the U.S. Food and Drug Administration or set by guidelines, and more than half of those received over 150% of that maximum. Pramipexole made up 67.6% of the high and very high dose prescriptions, and the top 1% of prescriptions were at least ten times the recommended maximum.

Low iron stores

In a re-analysis of a double-blind trial comparing cabergoline with levodopa, the 36 people with augmentation had a lower average serum ferritin (85 ng/mL) than the 302 without it (118 ng/mL). A 2023 meta-analysis of six observational studies, with 220 people with augmentation and 687 without, found augmentation significantly linked to low serum ferritin and to higher dopamine doses, but not significantly linked to higher symptom scores. These studies show an association; they do not show that raising ferritin prevents augmentation. In the Japanese cohort, both people who developed augmentation had ferritin above 110 ng/mL.

Longer treatment and more severe disease at the start

The community survey identified longer treatment, more frequent symptoms before treatment and greater discomfort before treatment as likely risk factors. The pramipexole and ropinirole trials both found that cases kept accumulating with time on the medicine.

Back to Table of Contents

Why the 2025 Guideline Changed

The American Academy of Sleep Medicine guideline, published in January 2025, ranks treatments by the strength of its recommendation. It gives strong recommendations for gabapentin enacarbil, gabapentin, pregabalin and intravenous ferric carboxymaltose (in people with appropriate iron status). For the dopamine medicines it uses this wording:

• “In adults with RLS, the AASM suggests against the standard use of pramipexole (conditional recommendation, moderate certainty of evidence).”
• Ropinirole: the same wording, moderate certainty of evidence.
• Transdermal rotigotine: the same wording, low certainty of evidence.
• Levodopa: the same wording, very low certainty of evidence.

Each of these four statements carries the same remark. For pramipexole it reads: “pramipexole may be used to treat RLS in patients who place a higher value on the reduction of restless legs symptoms with short-term use and a lower value on adverse effects with long-term use (particularly augmentation).” The guideline gives the same advice against standard use for levodopa and rotigotine in people with end-stage kidney disease.

“Conditional” has a specific meaning in the guideline. A strong recommendation is “one that clinicians should follow under most circumstances”; a conditional one leaves more room for individual choice. The guideline does not ban dopamine agonists, and it does not say they fail to work in the short term. Its wording points to the long-term adverse effects, and augmentation in particular, as the reason they are no longer a standard choice. The same guideline recommends against cabergoline, another dopamine agonist, as a strong recommendation.

The shift had been building for nearly a decade. In 2016 a combined task force of the International Restless Legs Syndrome Study Group, the European Restless Legs Syndrome Study Group and the RLS Foundation wrote that, as a way to prevent augmentation, alpha-2-delta ligands (gabapentin, gabapentin enacarbil and pregabalin) “may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation.”

Back to Table of Contents

How Consensus Statements Describe Management

No large controlled trial has tested how best to treat established augmentation. The pramipexole label states that “the frequency and severity of augmentation and/or rebound after longer-term use … and the appropriate management of these events have not been adequately evaluated in controlled clinical trials.” What exists is expert consensus plus observational studies.

The 2016 international task force

The task force of the International Restless Legs Syndrome Study Group, the European Restless Legs Syndrome Study Group and the RLS Foundation described a stepwise approach:

• First, where possible, removing or correcting outside factors that worsen symptoms — it names iron levels, antidepressants and antihistamines.
• In mild augmentation, continuing the dopamine agonist by dividing the dose or taking it earlier, or raising it if there are breakthrough night-time symptoms — or switching to an alpha-2-delta ligand or rotigotine.
• In severe augmentation, switching to an alpha-2-delta ligand or to rotigotine, with the caution that “rotigotine may also produce augmentation at higher doses with long-term use.”
• In more severe cases, an opioid, “bypassing” alpha-2-delta ligands and rotigotine.

The task force also stated that people with low iron stores should receive iron supplementation. The 2025 American Academy of Sleep Medicine guideline's iron thresholds — which it says “have not been empirically tested” — are given on the main page.

Switching to the rotigotine patch

A 13-month observational study followed 99 adults with augmentation on oral dopamine medicines who were switched to rotigotine at their own physician's discretion. Only 46 completed the observation period and 43 were assessed. Of those 43, 37 improved by at least one step on a global severity scale and 16 improved by 50% or more. The average time symptoms began moved from 12:38 to 18:25. Side effects (26 people) and lack of effect (14 people) were the most common reasons for stopping rotigotine, and 57 of the 99 took other restless legs medicines along the way.

Opioids

A 2018 statement from the Scientific and Medical Advisory Board of the RLS Foundation describes refractory restless legs syndrome — including cases where dopamine agonists fail through augmentation — as capable of causing “severely impaired quality of life, profound insomnia, and suicidal depression,” and calls opioid therapy “a mainstay” for these patients. It names oxycodone and methadone as the most commonly used, with tramadol, codeine, morphine and hydrocodone as alternatives. It reports effective doses far lower than in chronic pain (oxycodone 10–30 mg daily; methadone 5–20 mg daily) and states that the risk of opioid use disorder is “relatively low.” It also lists precautions: standard risk questionnaires, an opioid contract, urine drug screens, checks of state prescription monitoring programs and frequent reassessment. In the 10-year tertiary-center review, methadone showed no augmentation and no yearly discontinuation after the first year.

Rapid withdrawal with an alpha-2-delta ligand

A 2026 Spanish cohort tested a structured one-month protocol in 31 adults with clinically significant augmentation: rapid tapering of the dopamine agonist, correction of iron, and starting or raising an alpha-2-delta ligand, with the partial dopamine agonist aripiprazole added in some people whose symptoms worsened badly. Twenty-four (77%) were completely off the dopamine agonist after a month. Average symptom scores fell from 27.1 to 15.1 on the 0–40 scale, while the average gabapentin-equivalent dose rose from 417 to 1,288 mg a day. Those who could not withdraw had lived with augmentation much longer (11.4 against 3.5 years). This was an uncontrolled study of short-term results.

Back to Table of Contents

Impulse Control, Sleep Attacks and Other Side Effects

Augmentation is not the only long-term problem these studies report with dopamine agonists.

Impulse control disorders

The pramipexole label states that patients “can experience intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, binge eating, and/or other intense urges and the inability to control these urges” while taking medicines that increase dopamine activity. It adds that “in some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued,” and that patients may not recognise these behaviours as abnormal.

In a Mayo Clinic case-control study of 100 people treated with dopamine medicines for restless legs syndrome, confirmed rates after a phone interview were: compulsive shopping 9%, pathological gambling 5%, compulsive eating 11%, hypersexuality 3%, punding (repetitive, purposeless handling of objects) 7%, and any impulse control disorder 17%. These rates were significantly higher than in people with sleep apnea who had never taken such medicines. The study found a dose effect for pramipexole, and the problems began after an average of 9.5 months of treatment. In the 8-year pramipexole cohort, 10% developed impulse control disorders and two people stopped the medicine because of them; a related condition page covers gambling disorder.

Sleepiness and falling asleep without warning

The pramipexole label reports that people taking it have fallen asleep during daily activities, “including the operation of motor vehicles which sometimes resulted in accidents,” sometimes with no warning sign, and that some events happened as late as a year after starting. In its restless legs trials (0.25–0.75 mg once a day), somnolence occurred in 6% on pramipexole against 3% on placebo. In the 8-year cohort, 56% reported daytime sleepiness and 10% reported sleep attacks while driving.

Other label warnings

The pramipexole label also lists low blood pressure on standing (especially while the dose is being raised), hallucinations and psychotic-like behaviour (with risk rising with age), dyskinesia and postural deformity.

The alternatives carry their own risks

In the 52-week trial, six people on pregabalin reported suicidal thoughts, against three on pramipexole 0.25 mg and two on pramipexole 0.5 mg. The opioid trial results and side-effect rates are on the main page.

Back to Table of Contents

Coming Off a Dopamine Agonist

Stopping a dopamine agonist can be difficult for two separate reasons.

The first is rebound of restless legs symptoms. In the 26-week pramipexole trial reported on the label, people suddenly switched from pramipexole (up to 0.75 mg once daily) reported symptom scores worse than their untreated starting point more often than people on placebo (10% against 2%); the label calls the worsening “generally mild.” The Spanish withdrawal protocol above, in people who already had augmentation, combined the taper with iron correction and an alpha-2-delta ligand.

The second is dopamine agonist withdrawal syndrome. The pramipexole label states that “symptoms including apathy, anxiety, depression, fatigue, insomnia, sweating, and pain have been reported during taper or after discontinuation of dopamine agonists,” that these symptoms “generally do not respond to levodopa,” and that in severe cases re-starting a dopamine agonist at the lowest effective dose may be considered. A 2013 review described the syndrome as a severe, stereotyped cluster of physical and psychological symptoms that track the dose being withdrawn: anxiety, panic attacks, low mood, depression, agitation, irritability, suicidal thoughts, fatigue, dizziness on standing, nausea, vomiting, sweating, generalised pain and drug cravings. Some people recover fully; others have symptoms for months or years. The review reported that impulse control disorders were present in virtually all affected patients it described, and that at the time there were no known effective treatments for the syndrome. The review covers both Parkinson's disease and restless legs syndrome, and a 2013 case report describes the syndrome in a person with restless legs syndrome.

Back to Table of Contents

What Is Not Known

• The cause. The 2007 consensus conference listed the underlying biology of augmentation as an open question, and no later study cited here settles it.
• The true long-term rate. Controlled trials last 6 to 18 months and report single-digit rates, while long clinic and survey studies report 20–60%. The clinic cohorts are small (42 to 50 people in the two cited here), and the 6-month pramipexole trial enrolled only people with ferritin above 30 ng/mL.
• Whether iron prevents augmentation. Low ferritin is linked to augmentation in observational data, but no randomized trial cited here tested iron as a way to prevent it, and the American Academy of Sleep Medicine states its own iron thresholds have not been empirically tested.
• How best to treat it. The label states management has not been adequately evaluated in controlled trials; the evidence for switching to an alpha-2-delta ligand, rotigotine or an opioid comes from consensus statements and observational studies.
• Long-term data on the alternatives. The pregabalin comparison lasted 52 weeks. The 2016 meta-analysis found a 0.9% augmentation rate for gabapentin and pregabalin, and a 2007 case report described augmentation after long-term tramadol, an opioid, that eased once tramadol was stopped — its authors asked whether augmentation is “truly restricted to dopaminergic drugs.”
• Differences between populations. The Japanese cohort's 4.8% rate was far below Western cohorts; the authors could not say whether dose, iron or ancestry explained it.

Decisions about restless legs medicines belong with a clinician who knows the person's full history.

Back to Table of Contents

Key Research Papers

1. Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2025;21(1):137-152. PubMed PMID: 39324694
2. García-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Medicine. 2007;8(5):520-530. PubMed PMID: 17544323
3. Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine. 2016;21:1-11. PubMed PMID: 27448465
4. Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. New England Journal of Medicine. 2014;370(7):621-631. PubMed PMID: 24521108
5. Högl B, García-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. Journal of Neurology. 2010;257(2):230-237. PubMed PMID: 19756826
6. Högl B, Garcia-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Medicine. 2011;12(4):351-360. PubMed PMID: 21354368
7. García-Borreguero D, Högl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, Allen R. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Movement Disorders. 2012;27(2):277-283. PubMed PMID: 22328464
8. Beneš H, García-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Medicine. 2012;13(6):589-597. PubMed PMID: 22503658
9. Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurology. 2011;10(8):710-720. PubMed PMID: 21705273
10. Liu GJ, Wu L, Wang SL, Ding L, Xu LL, Wang YF, Chang LY. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(2):e2504. PubMed PMID: 26765466
11. Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Medicine. 2011;12(5):431-439. PubMed PMID: 21493132
12. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Medicine. 2011;12(5):440-444. PubMed PMID: 21239226
13. Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Medicine. 2012;13(10):1280-1285. PubMed PMID: 23036265
14. Tanioka K, Okura M, Inoue M, Taniguchi KI, Taniguchi M, Hamano T, Tachibana N. Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome. Neurological Sciences. 2018;39(9):1559-1564. PubMed PMID: 29845566
15. Trenkwalder C, Högl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Medicine. 2008;9(5):572-574. PubMed PMID: 17921065
16. Li YS, Yeh WC, Hsu CY. Association of low serum ferritin levels with augmentation in patients with restless legs syndrome: a systematic review and meta-analysis. Sleep Medicine. 2023;112:173-180. PubMed PMID: 37879259
17. Winkelman JW. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome. Sleep. 2022;45(2):zsab212. PubMed PMID: 34417810
18. Trenkwalder C, Canelo M, Lang M, Schroeder H, Kelling D, Berkels R, et al. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Medicine. 2017;30:257-265. PubMed PMID: 26896370
19. Silber MH, Becker PM, Buchfuhrer MJ, Earley CJ, Ondo WG, Walters AS, Winkelman JW. The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clinic Proceedings. 2018;93(1):59-67. PubMed PMID: 29304922
20. Martín García R, Boi S, Garcia-Malo C. Structured management of dopamine agonist withdrawal in restless legs syndrome with augmentation: a prospective real-world cohort study. Sleep Medicine. 2026;148:109238. PubMed PMID: 42673880
21. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33(1):81-87. PubMed PMID: 20120624
22. Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs & Aging. 2013;30(8):587-592. PubMed PMID: 23686524
23. Vetrugno R, La Morgia C, D'Angelo R, Loi D, Provini F, Plazzi G, Montagna P. Augmentation of restless legs syndrome with long-term tramadol treatment. Movement Disorders. 2007;22(3):424-427. PubMed PMID: 17230457
24. Dorfman BJ, Nirenberg MJ. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. Parkinsonism & Related Disorders. 2013;19(2):269-270. PubMed PMID: 22749683

Prescribing label: pramipexole dihydrochloride tablets, U.S. prescribing information, Warnings and Precautions sections on falling asleep during daily activities, impulse control and compulsive behaviors, withdrawal symptoms, and rebound and augmentation in restless legs syndrome (label version dated April 2026, via the U.S. Food and Drug Administration's openFDA drug label database).

PubMed Topic Searches

1. PubMed: augmentation with dopamine agonists in restless legs syndrome
2. PubMed: augmentation and ferritin
3. PubMed: impulse control disorders with dopaminergic treatment
4. PubMed: dopamine agonist withdrawal syndrome in restless legs syndrome

Back to Table of Contents

Connections

• Restless Legs Syndrome — the main page: diagnosis, iron and every treatment
• Ferritin Test — the iron-store measure linked to augmentation
• Iron Panel — ferritin, transferrin saturation and the rest
• Iron — the mineral at the centre of restless legs biology
• Gambling Disorder — one of the impulse control problems linked to dopamine agonists
• Parkinson's Disease — the other main use of the same medicines
• Non-Opioid Medications for Chronic Pain — gabapentin and pregabalin in another setting
• Neuropathic Pain — a condition often confused with restless legs

Back to Table of Contents

Featured Videos